Policy & Regulation
Bayer opens new research centre in Boston-Cambridge
29 June 2022 -

German multinational pharmaceutical and life sciences company Bayer AG (ETR:BAYN) has opened a new Research and Innovation Center in the United States, the company announced on Wednesday.

Located at Kendall Square in Boston-Cambridge, Massachusetts, this 62,100 sq ft facility houses a new centre of precision molecular oncology research equipped with state-of-the-art laboratories and offices for the development of novel targeted cancer therapies.

In addition, a newly established research team will focus on leveraging chemical biology techniques to further advance the company's oncology drug development process.

Bayer's investment in the new facility amounts to USD140m.

Boston-Cambridge is home to approximately 1,000 biotechnology companies, with Kendall Square being the centre of pharmaceutical innovation on the East Coast of the US, Bayer said. The company is now present in four of the largest biotechnology hubs in the country: Boston, San Francisco, San Diego and Research Triangle Park, North Carolina.